Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …

Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …

ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

It is unclear whether a single clone metastasizes and remains dominant over the course of
lethal prostate cancer. We describe the clonal architectural heterogeneity at different stages …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …